<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>BPC-157: what changed | Grey Peptides</title>
    <link>https://greypeptides.com/changes/#e-bpc-157</link>
    <atom:link href="https://greypeptides.com/changes/bpc-157.xml" rel="self" type="application/rss+xml" />
    <description>News, regulatory alerts, corrections and new guides about BPC-157 on Grey Peptides, newest first.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 18 Nov 2026 12:00:00 +0000</lastBuildDate>
    <ttl>1440</ttl>
    <item>
      <title>New guide: What lab testing shows</title>
      <link>https://greypeptides.com/testing/#c-bpc-157</link>
      <guid isPermaLink="false">greypeptides-changes-bpc-157-guide-/testing/#c-bpc-157</guid>
      <pubDate>Wed, 18 Nov 2026 12:00:00 +0000</pubDate>
      <category>New guide</category>
      <description>The largest analysis of grey-market test results (a preprint): purity, amount, identity and endotoxin.</description>
    </item>
    <item>
      <title>New guide: BPC-157: the legal prescription route</title>
      <link>https://greypeptides.com/legal-access/bpc-157/</link>
      <guid isPermaLink="false">greypeptides-changes-bpc-157-guide-/legal-access/bpc-157/</guid>
      <pubDate>Wed, 18 Nov 2026 12:00:00 +0000</pubDate>
      <category>New guide</category>
      <description>Which forms HHS's interim 503A policy covers, the conditions, licensed pharmacies that announced it, and what FDA found.</description>
    </item>
    <item>
      <title>News: Did FDA Give Pharmacies the Green Light on Six Peptides? What Changed on October 30</title>
      <link>https://greypeptides.com/news/hhs-peptide-compounding-policy-fact-check/</link>
      <guid isPermaLink="false">greypeptides-changes-bpc-157-news-hhs-peptide-compounding-policy-fact-check</guid>
      <pubDate>Wed, 04 Nov 2026 12:00:00 +0000</pubDate>
      <category>News</category>
      <description>Did FDA Give Pharmacies the Green Light on Six Peptides? What Changed on October 30</description>
    </item>
    <item>
      <title>Regulatory alert: US HHS (Office of the Secretary): HHS published a policy saying it does not intend to take enforcement action against state-licensed pharmacies, federal facilities and physicians that compound BPC-157, TB-500, MOTS-c, KPV, semax or epitalon under set forms, routes and conditions, while FDA writes the 503A bulks list by rulemaking (91 FR 68526).</title>
      <link>https://greypeptides.com/regulatory/alerts/#hhs-peptide-enforcement-discretion</link>
      <guid isPermaLink="false">greypeptides-changes-bpc-157-alert-hhs-peptide-enforcement-discretion</guid>
      <pubDate>Fri, 30 Oct 2026 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>Enforcement discretion, not a rule or an approval: the policy is non-binding, HHS may revisit it, and the conditions cover sourcing, a certificate of analysis, one peptide per product, labelling, an FDA-cleared syringe and adverse-event reporting. None of the six is on the 503A list or in Category 1; emideltide is not covered, and products sold outside a pharmacy are not covered.</description>
    </item>
    <item>
      <title>Correction: Corrected: BPC-157</title>
      <link>https://greypeptides.com/corrections/#c-q905-bpc157-halflife</link>
      <guid isPermaLink="false">greypeptides-changes-bpc-157-corr-c-q905-bpc157-halflife</guid>
      <pubDate>Wed, 28 Oct 2026 12:00:00 +0000</pubDate>
      <category>Correction</category>
      <description>Half-life under 30 minutes in rats and dogs, the only species in which it has been measured.</description>
    </item>
    <item>
      <title>News: WADA's 2027 Prohibited List Writes 'Peptides' Into Its Catch-All Ban</title>
      <link>https://greypeptides.com/news/wada-2027-prohibited-list-peptides/</link>
      <guid isPermaLink="false">greypeptides-changes-bpc-157-news-wada-2027-prohibited-list-peptides</guid>
      <pubDate>Wed, 30 Sep 2026 12:00:00 +0000</pubDate>
      <category>News</category>
      <description>WADA's 2027 Prohibited List Writes 'Peptides' Into Its Catch-All Ban</description>
    </item>
    <item>
      <title>Regulatory alert: US FDA advisory committee: The Pharmacy Compounding Advisory Committee voted to recommend BPC-157, KPV, TB-500, MOTS-c, semax and epitalon for FDA's 503A bulks list and voted against emideltide, as reported (BPC-157 8–6, 1 abstention; KPV 8–6, 1 abstention; TB-500 8–6, 1 abstention; MOTS-c 7–5, 2 abstentions; emideltide 6–7, 1 abstention; semax 8–5, 1 abstention; epitalon 7–4 or 7–5, 1 abstention).</title>
      <link>https://greypeptides.com/regulatory/alerts/#pcac-july-2026-votes</link>
      <guid isPermaLink="false">greypeptides-changes-bpc-157-alert-pcac-july-2026-votes</guid>
      <pubDate>Fri, 24 Jul 2026 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>A committee recommendation is not a rule. As of November 4, 2026, FDA had posted no minutes or tallies, its 503A category list was still dated May 14, 2026, and none of the six was on the list or in Category 1. HHS's October 30 enforcement-discretion policy, logged separately, covers compounding of the six under its conditions; it does not add them to the list.</description>
    </item>
    <item>
      <title>Regulatory alert: Brazil (ANVISA): Brazil's health regulator said GHK-Cu, BPC-157, TB-500, CJC-1295 and ipamorelin are not registered in any category and are illegal for any health or aesthetic use.</title>
      <link>https://greypeptides.com/regulatory/alerts/#anvisa-peptides-not-registered</link>
      <guid isPermaLink="false">greypeptides-changes-bpc-157-alert-anvisa-peptides-not-registered</guid>
      <pubDate>Thu, 02 Jul 2026 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>In Brazil an injectable peptide cannot be sold as a supplement or a cosmetic: supplements cannot be injectable and injectable cosmetics do not exist in its rules.</description>
    </item>
    <item>
      <title>Regulatory alert: France (ANSM): France's medicines agency told the public not to buy or inject peptides sold online, on social media or through informal contacts, naming retatrutide, BPC-157, TB-500 and GHK-Cu among others. Updated August 31.</title>
      <link>https://greypeptides.com/regulatory/alerts/#ansm-peptides-online-warning</link>
      <guid isPermaLink="false">greypeptides-changes-bpc-157-alert-ansm-peptides-online-warning</guid>
      <pubDate>Thu, 02 Jul 2026 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>In France these products are neither evaluated nor authorised, and their contents are uncertain. Anyone who has used them and has side effects should see a health professional.</description>
    </item>
    <item>
      <title>Regulatory alert: Louisiana: Louisiana enacted Act 374 (Senate Bill 253), effective August 1, 2026: licensing boards may not bar prescribers or pharmacists from peptides compounded by pharmacies or outsourcing facilities that comply with the federal compounding statutes.</title>
      <link>https://greypeptides.com/regulatory/alerts/#louisiana-act-374</link>
      <guid isPermaLink="false">greypeptides-changes-bpc-157-alert-louisiana-act-374</guid>
      <pubDate>Fri, 22 May 2026 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>It sounds permissive but adds no ingredient: federal law still decides what may be compounded, so BPC-157 and most popular peptides remain out of reach. It protects only compounding that is already federally lawful.</description>
    </item>
    <item>
      <title>Regulatory alert: US FDA: FDA's list of substances that may present significant safety risks now shows twelve peptides, including BPC-157, TB-500, KPV and MOTS-c, among nominations withdrawn, so they are no longer in Category 2.</title>
      <link>https://greypeptides.com/regulatory/alerts/#category-2-twelve-withdrawn</link>
      <guid isPermaLink="false">greypeptides-changes-bpc-157-alert-category-2-twelve-withdrawn</guid>
      <pubDate>Wed, 22 Apr 2026 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>Off Category 2 is not cleared: none moved to Category 1 or onto the 503A list, so 503A pharmacies still cannot compound them. Seven went to the July committee; five wait for a meeting before the end of February 2027.</description>
    </item>
    <item>
      <title>Regulatory alert: US FDA: FDA gave notice in the Federal Register (91 FR 20465) of a July 23-24, 2026 committee meeting on seven peptides nominated for the 503A bulks list: BPC-157, KPV, TB-500, MOTS-c, emideltide, semax and epitalon.</title>
      <link>https://greypeptides.com/regulatory/alerts/#pcac-july-meeting-noticed</link>
      <guid isPermaLink="false">greypeptides-changes-bpc-157-alert-pcac-july-meeting-noticed</guid>
      <pubDate>Thu, 16 Apr 2026 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>The first public review of these peptides for compounding, with a public docket (FDA-2025-N-6895) that took comments until July 22.</description>
    </item>
    <item>
      <title>Regulatory alert: Ohio: Ohio's Board of Pharmacy updated its guidance on clinic and medical-spa violations: BPC-157 and other substances in FDA's Categories 2 and 3 cannot be compounded, and it has summarily suspended more than 30 clinics and medical spas since the start of 2025.</title>
      <link>https://greypeptides.com/regulatory/alerts/#ohio-board-guidance</link>
      <guid isPermaLink="false">greypeptides-changes-bpc-157-alert-ohio-board-guidance</guid>
      <pubDate>Mon, 08 Dec 2025 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>Ohio acts on a clinic's licence rather than waiting for FDA. BPC-157 has since left Category 2, but it is still not compoundable under federal law.</description>
    </item>
  </channel>
</rss>
